• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Frequency of ERBB2-Low Expression in Endometrial Cancer.

作者信息

Krakstad Camilla, Berg Hege F, Lindemann Kristina, Halle Mari Kyllesø

机构信息

Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.

Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.

出版信息

JAMA Oncol. 2024 Nov 1;10(11):1587-1588. doi: 10.1001/jamaoncol.2024.3660.

DOI:10.1001/jamaoncol.2024.3660
PMID:39235791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11378060/
Abstract
摘要

相似文献

1
Frequency of ERBB2-Low Expression in Endometrial Cancer.子宫内膜癌中ERBB2低表达的频率
JAMA Oncol. 2024 Nov 1;10(11):1587-1588. doi: 10.1001/jamaoncol.2024.3660.
2
Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer.血清表皮生长因子、转化生长因子和 c-erbB2 在卵巢癌中的水平。
Int J Gynecol Cancer. 2012 Sep;22(7):1138-42. doi: 10.1097/IGC.0b013e31825b7dcc.
3
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.AEE788：一种双靶点的表皮生长因子受体/ErbB2及血管内皮生长因子受体酪氨酸激酶抑制剂，具有抗肿瘤和抗血管生成活性。
Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681.
4
Automated Classification of Breast Cancer Across the Spectrum of Expression Focusing on Heterogeneous Tumors With Low Human Epidermal Growth Factor Receptor 2 Expression.基于人表皮生长因子受体 2 低表达的异质性肿瘤，聚焦于表达谱的乳腺癌全自动分类。
JCO Clin Cancer Inform. 2023 Jul;7:e2300013. doi: 10.1200/CCI.23.00013.
5
Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.乳腺癌分子类别ERBB2：具有大汗腺分化以及基底表型标志物CK5、CK5/6和表皮生长因子受体（EGFR）表达的肿瘤占优势。
Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.
6
Prognostic significance of c-erbB2 protein in endometrial cancer.c-erbB2蛋白在子宫内膜癌中的预后意义
Rom J Morphol Embryol. 1998 Jan-Dec;44(1-4):101-7.
7
Active G protein-coupled receptors (GPCR), matrix metalloproteinases 2/9 (MMP2/9), heparin-binding epidermal growth factor (hbEGF), epidermal growth factor receptor (EGFR), erbB2, and insulin-like growth factor 1 receptor (IGF-1R) are necessary for trenbolone acetate-induced alterations in protein turnover rate of fused bovine satellite cell cultures.活性G蛋白偶联受体（GPCR）、基质金属蛋白酶2/9（MMP2/9）、肝素结合表皮生长因子（hbEGF）、表皮生长因子受体（EGFR）、erbB2和胰岛素样生长因子1受体（IGF-1R）是醋酸群勃龙诱导融合牛卫星细胞培养物蛋白质周转率改变所必需的。
J Anim Sci. 2016 Jun;94(6):2332-43. doi: 10.2527/jas.2015-0178.
8
Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.同源重组 mRNA（RAD21、RAD50 和 BARD1）在 ERBB2 低表达膀胱癌患者中具有潜在的不良预后作用。
Sci Rep. 2023 Jul 20;13(1):11738. doi: 10.1038/s41598-023-38923-y.
9
Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.胶质瘤和脑膜瘤中的表皮生长因子受体家族（EGFR、ErbB2 - 4）
Acta Neuropathol. 2004 Aug;108(2):135-42. doi: 10.1007/s00401-004-0875-6. Epub 2004 May 18.
10
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.ERBB2 突变定义了一组子宫内膜癌亚群，这些亚群与高肿瘤突变负担和微卫星不稳定高（MSI-H）分子亚型相关。
Mol Oncol. 2024 Oct;18(10):2356-2368. doi: 10.1002/1878-0261.13698. Epub 2024 Jul 19.

引用本文的文献

1
HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups.子宫内膜癌中HER2扩增与HER2低表达：分子、组织学及临床病理风险组的患病率
BJC Rep. 2025 Feb 12;3(1):8. doi: 10.1038/s44276-025-00125-6.

本文引用的文献

1
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.曲妥珠单抗-德鲁替康在 HER2 表达的实体瘤患者中的疗效和安全性：来自 DESTINY-PanTumor02 Ⅱ期试验的初步结果。
J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23.
2
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.HER2基因蛋白检测：评估子宫内膜癌中HER2状态和肿瘤内异质性的有力工具。
Am J Clin Pathol. 2023 May 2;159(5):464-473. doi: 10.1093/ajcp/aqac179.
3
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.配对原发性和转移性子宫内膜癌病变中 HER2 的表达模式。
Br J Cancer. 2018 Feb 6;118(3):378-387. doi: 10.1038/bjc.2017.422. Epub 2017 Nov 23.
4
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.针对子宫内膜浆液性癌的 HER2 检测标准化：大型学术中心的 4 年经验及临床实践建议。
Mod Pathol. 2013 Dec;26(12):1605-12. doi: 10.1038/modpathol.2013.113. Epub 2013 Jun 14.
5
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.曲妥珠单抗治疗晚期或复发性HER2阳性子宫内膜癌女性的II期试验：一项妇科肿瘤学组研究
Gynecol Oncol. 2010 Jan;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025. Epub 2009 Oct 18.